Literature DB >> 30052509

90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2.

Geoffrey S Gottlieb1, Dana N Raugi2, Robert A Smith2.   

Abstract

Distinct from HIV-1 and often neglected in the global campaign to end the AIDS epidemic, HIV-2 presents unique and underappreciated challenges in diagnosis, clinical care, antiretroviral therapy (ART), and HIV programmatic management. Here, we review the epidemiology and natural history of HIV-2, diagnostics and algorithms for accurately diagnosing and differentiating HIV-2 from HIV-1, the unique features of HIV-2 ART and drug resistance, and the clinical care and management of patients infected with HIV-2 in both developed and resource-limited settings. Ultimately, further research is needed to address the gaps in our knowledge of HIV-2 infection, increased resources are needed to specifically target HIV-2 as part of the UNAIDS/WHO 90-90-90 campaign to end AIDS, and increased determination is needed to better advocate for inclusion of people living with HIV-2 in global HIV/AIDS initiatives.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30052509     DOI: 10.1016/S2352-3018(18)30094-8

Source DB:  PubMed          Journal:  Lancet HIV        ISSN: 2352-3018            Impact factor:   12.767


  17 in total

1.  Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Authors:  Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

2.  Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.

Authors:  Morgan E Meissner; Nora A Willkomm; Jamie Lucas; William G Arndt; Sarah F Aitken; Emily J Julik; Sunanda Baliga; Louis M Mansky
Journal:  J Mol Biol       Date:  2021-11-10       Impact factor: 5.469

3.  Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.

Authors:  Robert A Smith; Vincent H Wu; Jennifer Song; Dana N Raugi; Khardiata Diallo Mbaye; Moussa Seydi; Geoffrey S Gottlieb
Journal:  J Infect Dis       Date:  2022-08-26       Impact factor: 7.759

4.  HIV-2 Drug Resistance Genotyping from Dried Blood Spots.

Authors:  Dana N Raugi; Robert S Nixon; Sally Leong; Khadim Faye; Jean Phillipe Diatta; Fatima Sall; Robert A Smith; ElHadji Ibrahima Sall; Jean Jacques Malomar; Moussa Seydi; Geoffrey S Gottlieb
Journal:  J Clin Microbiol       Date:  2020-12-17       Impact factor: 5.948

5.  Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2.

Authors:  Philip L Tzou; Diane Descamps; Soo-Yon Rhee; Dana N Raugi; Charlotte Charpentier; Nuno Taveira; Robert A Smith; Vicente Soriano; Carmen de Mendoza; Susan P Holmes; Geoffrey S Gottlieb; Robert W Shafer
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 5.226

6.  In Vitro Antiviral Activity of Cabotegravir against HIV-2.

Authors:  Robert A Smith; Vincent H Wu; Christopher G Zavala; Dana N Raugi; Selly Ba; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

7.  An HIV Diagnostic Testing Algorithm Using the cobas HIV-1/HIV-2 Qualitative Assay for HIV Type Differentiation and Confirmation.

Authors:  Dana Duncan; John Duncan; Bastian Kramer; Alex Y Nilsson; Betiel Haile; Ann Butcher; Shikha Chugh; Paul Baum; Grace M Aldrovandi; Stephen Young; Ann K Avery; Karen Tashima; Alexandra Valsamakis; Joseph D Yao; Ming Chang; Robert W Coombs
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

8.  Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.

Authors:  Dana N Raugi; Selly Ba; Ousseynou Cisse; Khardiata Diallo; Ibrahima Tito Tamba; Cheikh Ndour; Ndeye Mery Dia Badiane; Louise Fortes; Mouhamadou Baïla Diallo; Dominique Faye; Robert A Smith; Fatima Sall; Macoumba Toure; ElHadji Ibrahima Sall; Habibatou Diallo Agne; Khadim Faye; Jean Philippe Diatta; Marie Pierre Sy; Ming Chang; Binetou Diaw; Jacques Sambou; Raphael Bakhoum; Mame Demba Sy; Alassane Niang; Jean Jacques Malomar; Robert W Coombs; Stephen E Hawes; Ibra Ndoye; Nancy B Kiviat; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb
Journal:  Clin Infect Dis       Date:  2021-02-01       Impact factor: 20.999

Review 9.  The Interplay between Viruses and Host DNA Sensors.

Authors:  Sandra Huérfano; Vojtech Šroller; Kateřina Bruštíková; Lenka Horníková; Jitka Forstová
Journal:  Viruses       Date:  2022-03-23       Impact factor: 5.818

10.  Long-term immunological responses to treatment among HIV-2 patients in Côte d'Ivoire.

Authors:  Peter A Minchella; Christiane Adjé-Touré; Guoqing Zhang; Andre Tehe; Judith Hedje; Erin R Rottinghaus; Natacha Kohemun; Micheline Aka; Karidia Diallo; G Laissa Ouedraogo; Kevin M De Cock; John N Nkengasong
Journal:  BMC Infect Dis       Date:  2020-03-12       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.